Sandoz And AbbVie Biosimilar Humira Settlement: What Does It Mean?

 
• By Eleanor Malone and Kevin Grogan

Sandoz has become the latest firm to sign a settlement agreement over biosimilar Humira with AbbVie, heralding imminent launch in Europe. In the US, it will hold off launching until September 2023.

Greyhounds
Starter's orders - but who will be fast out of the traps? • Source: Shutterstock

More from Legal & IP

More from Business